Hepatitis/MASH

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.

New procedure seeks to guide therapeutic decisions.

Drug cost mitigated by savings in health care costs on management of conditions that may result from chronic hepatitis C virus.

Treating hepatitis C patients who receive health care through Medicaid with Sovaldi could exceed $55 billion.

Combination of grazoprevir and elbasvir has been studied in patients with genotype 1 hepatitis C who also have end-stage renal disease and are undergoing regular hemodialysis.

Shorter duration could reduce the economic impact on health care spending and make treatment more convenient.

New culturing method leads to highly therapeutic cells that grow faster and stronger.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Includes evidence-based advice on the best use for next generation direct-acting antivirals.

Here are new drugs for 2015 that pharmacists can expect to handle.

Exchange plan spending on hepatitis C drugs increased 96% in the first quarter of 2015.

Preliminary evidence suggests that the first-generation antihistamines chlorcyclizine and hydroxyzine may fight HCV infection for pennies a day.

Hydrogel prevents drugs from prematurely leaving the body.

Many states implement unlawful and life-threatening restrictions on Medicaid coverage for the hepatitis C virus drug, sofosbuvir.

Coverage restrictions on wrong side of Medicaid law requiring states to cover drugs consistent with FDA labels.

Patients with genotype 1b hepatitis C achieve sustained virologic response after 12 weeks.

California's Affordable Care Act health insurance exchange marketplace is the first in the nation to enact a payment cap policy for expensive specialty drugs.

Preventative measures emphasized to reduce transmission of disease.

Early research in HIV and hepatitis B discontinued.

Gaining approval from insurance companies for highly effective new hepatitis C virus treatments is fraught with challenges for patients.

Advocacy group staffed by hepatitis C patients helps others find hope in fight against the disease.

New hepatitis C drugs moved the dream of a cure into a reality that gives patients a new chance at life.

Hyperlipidemia found to alter immune response.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.